X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2655) 2655
Publication (281) 281
Book Review (67) 67
Newsletter (42) 42
Book Chapter (26) 26
Conference Proceeding (5) 5
Data Set (3) 3
Dissertation (2) 2
Transcript (2) 2
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1963) 1963
ribavirin (1572) 1572
index medicus (1452) 1452
antiviral agents - therapeutic use (1111) 1111
hepatitis c, chronic - drug therapy (1058) 1058
hepatitis c (1056) 1056
male (955) 955
female (911) 911
hepatitis c virus (792) 792
ribavirin - therapeutic use (790) 790
gastroenterology & hepatology (789) 789
drug therapy, combination (767) 767
middle aged (760) 760
interferon (722) 722
pharmacology & pharmacy (721) 721
adult (685) 685
treatment outcome (634) 634
interferon-alpha - therapeutic use (605) 605
hepacivirus - genetics (548) 548
antiviral agents - administration & dosage (535) 535
hepacivirus - drug effects (500) 500
plus ribavirin (485) 485
antiviral agents - adverse effects (475) 475
virus-infection (454) 454
hepatitis (451) 451
genotype (448) 448
therapy (442) 442
antiviral agents (437) 437
hepatitis c - drug therapy (433) 433
ribavirin - administration & dosage (432) 432
recombinant proteins (426) 426
health aspects (424) 424
polyethylene glycols - therapeutic use (422) 422
infection (390) 390
pharmacokinetics (389) 389
antiviral agents - pharmacokinetics (370) 370
aged (356) 356
antiviral agents - pharmacology (356) 356
animals (352) 352
virology (348) 348
drug therapy (342) 342
hepatitis c, chronic - virology (340) 340
infectious diseases (336) 336
biological response modifiers (334) 334
hcv (322) 322
care and treatment (320) 320
ribavirin - adverse effects (298) 298
interferon-alpha - administration & dosage (297) 297
peginterferon alpha-2a (286) 286
chronic hepatitis-c (284) 284
sustained virological response (284) 284
pegylated interferon (283) 283
combination therapy (269) 269
telaprevir (266) 266
virus diseases (263) 263
liver (253) 253
viral load (252) 252
ribavirin - pharmacokinetics (239) 239
analysis (232) 232
sofosbuvir (231) 231
peginterferon (222) 222
combination (221) 221
interferon-alpha - adverse effects (221) 221
viruses (221) 221
infections (220) 220
rna, viral - blood (218) 218
initial treatment (207) 207
polyethylene glycols - administration & dosage (201) 201
recombinant proteins - therapeutic use (200) 200
efficacy (198) 198
dose-response relationship, drug (197) 197
cirrhosis (194) 194
genetic aspects (194) 194
antiviral therapy (189) 189
chronic hepatitis c (189) 189
protease inhibitors (189) 189
hepatitis c, chronic - complications (187) 187
gastroenterology and hepatology (185) 185
virus (184) 184
research (178) 178
microbiology (175) 175
genotype 1 infection (174) 174
medicine & public health (174) 174
transplantation (174) 174
randomized-trial (173) 173
ribavirin - pharmacology (172) 172
safety (171) 171
treatment-naive patients (170) 170
drug interactions (169) 169
hepatology (169) 169
polyethylene glycols - adverse effects (167) 167
genotype & phenotype (166) 166
clinical trials (164) 164
liver cirrhosis (162) 162
hiv (160) 160
young adult (156) 156
liver transplantation (155) 155
rna (154) 154
viral nonstructural proteins - antagonists & inhibitors (154) 154
interferon-alpha-2b plus ribavirin (151) 151
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2682) 2682
Japanese (7) 7
Spanish (7) 7
French (6) 6
Korean (6) 6
Russian (5) 5
German (4) 4
Dutch (2) 2
Hungarian (2) 2
Polish (2) 2
Turkish (2) 2
Arabic (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2016, Volume 60, Issue 1, pp. 105 - 114
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 10/2017, Volume 56, Issue 10, pp. 1115 - 1124
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 3/2013, Volume 56, Issue 5, pp. 718 - 726
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 4, pp. 805 - 812
Background & Aims Paritaprevir, ombitasvir, and dasabuvir are direct-acting antivirals for treatment of chronic hepatitis C virus (HCV) infection. The aim of... 
Gastroenterology and Hepatology | Direct-acting antiviral agents | Ombitasvir | Chronic hepatitis C | Hepatic impairment | Ritonavir | Paritaprevir | Pharmacokinetics | Dasabuvir | ABT-450/R-OMBITASVIR | TRANSPORTER EXPRESSION | RIBAVIRIN | LIVER-DISEASE | GENOTYPE 1 | THERAPY | CIRRHOSIS | HCV | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Carbamates - pharmacokinetics | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Ribavirin - pharmacokinetics | Female | Drug Therapy, Combination | Liver Function Tests | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Ritonavir - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatic Insufficiency - blood | Hepatitis C, Chronic - blood | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Macrocyclic Compounds - administration & dosage | Hepatic Insufficiency - etiology | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Safety and security measures | Hepatitis C virus | Hepatitis C
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 05/2015, Volume 15, Issue 5, pp. 1313 - 1322
ABT‐450, ombitasvir, and dasabuvir are direct‐acting antiviral agents (DAAs) that have been developed for combination treatment of chronic hepatitis C virus... 
infectious disease | clinical research/practice | pharmacology | calcineurin inhibitor: cyclosporine A (CsA) | pharmacokinetics/pharmacodynamics | immunosuppressant | infection and infectious agents | calcineurin inhibitor: tacrolimus | liver transplantation/hepatology | viral: hepatitis C | SURGERY | ABT-450/R-OMBITASVIR | LIVER-TRANSPLANTATION | EFFICACY | DRUG-INTERACTIONS | TRANSPORTERS | INFECTION | HCV | RIBAVIRIN | INHIBITOR | HEPATITIS-C | TRANSPLANTATION | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Area Under Curve | Humans | Middle Aged | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Healthy Volunteers | Carbamates - pharmacokinetics | Young Adult | Uracil - administration & dosage | Cyclosporine - pharmacokinetics | Adult | Female | Tacrolimus - administration & dosage | Hepacivirus - drug effects | Drug Administration Schedule | Macrocyclic Compounds - pharmacokinetics | Tacrolimus - pharmacokinetics | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Anilides - administration & dosage | Adolescent | Cyclosporine - administration & dosage | Macrocyclic Compounds - administration & dosage | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Dosage and administration | Liver diseases | Drug therapy, Combination | Tacrolimus | Hepatitis C virus | Hepatitis C | Hepatitis | Medical research | Drug dosages | practice | pharmacodynamics | hepatology | clinical research | pharmacokinetics | Original | liver transplantation
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 03/2017, Volume 83, Issue 3, pp. 527 - 539
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2014, Volume 53, Issue 5, pp. 409 - 427
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 04/2016, Volume 62, Issue 8, pp. 972 - 979
Background. Guidelines for the treatment of human immunodeficiency virus (HIV) infection consistently recommend initiation of antiretroviral therapy in... 
pharmacokinetics | direct-acting antiviral HCV drugs | HIV | hepatitis C | HIV protease inhibitors | INFECTIOUS DISEASES | ABT-450/R-OMBITASVIR | MICROBIOLOGY | RIBAVIRIN | IMMUNOLOGY | THERAPY | HCV | RITONAVIR | Anilides - therapeutic use | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Coinfection - drug therapy | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Healthy Volunteers | Carbamates - pharmacokinetics | Young Adult | Drug Therapy, Combination - adverse effects | Drug Interactions | Uracil - administration & dosage | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | Hepatitis C - complications | HIV Protease Inhibitors - adverse effects | Hepacivirus - drug effects | Drug Administration Schedule | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | HIV-1 - drug effects | HIV Infections - virology | Macrocyclic Compounds - pharmacokinetics | Uracil - therapeutic use | HIV Protease Inhibitors - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Coinfection - virology | Sulfonamides - pharmacokinetics | Macrocyclic Compounds - therapeutic use | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Sulfonamides - therapeutic use | Adolescent | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Care and treatment | Research | Hepatitis C virus | HIV (Viruses) | Patients | Health aspects | Methods
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 09/2015, Volume 104, Issue 9, pp. 2813 - 2823
Journal Article